Please assess the completion status of the following clinical trial:

Trial Title: Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a partial response (PR) or better prior to allo-transplantation~* Relapsed MM with chemo sensitivity disease, with or without prior autologous HSCT~* First allogenic transplant~* Donors can be haploidentical, mismatch or matched related or unrelated. Stem cell source will be peripheral blood except for haploidentical where stem cell source will be bone marrow~* Ejection fraction \>= 45%~* Estimated creatinine clearance greater than 40 mL/minute~* Diffusion capacity of the lung for carbon monoxide (DLCO) \>= 40% (adjusted for hemoglobin)~* Forced expiratory volume in 1 second (FEV1) \>= 50%~* Total bilirubin \< 2 x the upper limit of normal~* Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) \< 2.5 x the upper normal limit~* Signed informed consent~Exclusion Criteria:~* Patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin change (POEMS), Waldenstrom macroglobulinemia~* Uncontrolled bacterial, viral or fungal infection~* Patients with prior malignancies \< 3 years except resected basal cell/squamous cell carcinoma, treated carcinoma in-situ. Other cancers treated with curative intent \< 3 years previously will not be allowed unless approved by the principal investigator~* Female patients who are pregnant or breastfeeding. A negative pregnancy test will be required for all women of child bearing potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (conditioning regimen, stem cell transplant) (Type: EXPERIMENTAL): Patients receive fludarabine IV on days -5 to -2 and melphalan IV on days -3 to -2, then undergo stem cell transplantation on day 0. Patients receive cyclophosphamide on days 3 and 4, tacrolimus PO BID or IV starting on day 5, and mycophenolate mofetil IV or PO TID on days 5 to 35. Patients also receive daratumumab IV starting between days 90-150 for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).